Hemofarm announces continuation of investments in new facilities and modernization of business

The leader in the pharmaceutical market of Serbia and the region, one of ten largest exporters in Serbia - the company Hemofarm, celebrated 58 years of successful business operation and announced new investments in new facilities and the modernization of its business.

The company's press release says that, over the course of last year, Hemofarm accomplished new business successes and became the main hub of the STADA Group, within which it operates, for the central European markets (Poland, Czech Republic and Slovakia), whereby it expanded the area of its competence to total 13 countries of central and South-East Europe.

The construction of the state-of-the-art Packaging Center in Vrsac, an investment worth 21.6 million euros, was successfully completed, while a new plant for production of sterile nasal sprays (SNUP) was constructed within Hemomont factory in Podgorica.

Since August 2006, when Hemofarm became a part of German Stada Group, about 300 million euros have been invested in modernization of operations, equipment and new plants, and new investments are also planned, the press release adds.

– I am proud that we have maintained the leadership position in Serbia, Bosnia and Herzegovina and Montenegro and that we are making strong progress in other markets – says Ronald Seeliger, CEO of Hemofarm.

The press release also points out that future plans of Hemofarm are closely related to further strengthening and internationalization of operations of Stada, which intends to become one of five largest generic producers in the world.

Hemofarm a.d. Vršac

Stada Beograd-obrisano iz rgistra

Hemofarm

Stada

Hemofarm Packaging Center in Vrsac

Hemomont

plant for production of sterile nasal sprays SNUP Hemofarm Podgorica

generic medicines

production of generic medicines

Hemofarm investments